Clinical Trial Update: FFOCT for the Diagnosis of Prostate Cancer

View source ↗

Summary

A completed clinical trial evaluating FFOCT as a diagnostic tool for prostate cancer in men with a PSA of 4.0 ng/mL.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Patients With PSA Level 4.0 ng/mL | Status: COMPLETED